Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
In this study, the investigators test 2 dose levels of thiotepa (5 mg/kg and 10 mg/kg) added
to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte
globulin (rATG) to determine the minimum effective dose required for reliable engraftment for
subjects undergoing hematopoietic stem cell transplantation for non-malignant disease.